Pharmaceutical industry: New perspectives taking shape
Tunisia has taken strategic measures to strengthen its autonomy in the pharmaceutical sector. A recent working meeting held at the Ministry of Health resulted in a series of decisions aimed at accelerating the licensing procedures for medicines, ensuring their rapid availability on the market.
These decisions include enhancing export opportunities, expanding regional partnerships to position Tunisia as a pharmaceutical hub, and digitizing the sector to ensure transparency and smooth distribution.
Present at the meeting, Health Minister Mustapha Ferjani emphasized the directives of the President of the Republic, which aim to achieve pharmaceutical sovereignty, boost local production, and rely on national expertise to ensure health security.
The meeting brought together representatives from the National Chamber of the Pharmaceutical Industry (CNIP) as well as directors of structures involved in the pharmaceutical sector.
The adopted measures also include encouraging investments in pharmaceutical industries, supporting new laboratories, and revising price compensation mechanisms to protect the competitiveness of local manufacturers. These initiatives reflect the nation's commitment to achieving true health autonomy, aiming to meet citizens' needs and reduce dependence on foreign imports.
Over 20% of Medicines Produced in Tunisia Are Exported
More than 20% of medicines manufactured in Tunisia are exported to numerous countries, including Libya, sub-Saharan Africa, the Middle East, and Europe, according to Nadia Fenina, Director General of the Investment and Export Promotion Unit for Health Services at the Ministry of Health.
In a recent statement to the media on the sidelines of the first International Days of Generic Medicines and Biosimilars held in Tunis, Fenina revealed that the value of these exports ranges between 250 and 300 million dinars. 'The goal is to reach 1.4 billion dinars within four years,' she noted.
Fenina emphasized that this target was set based on the results of a strategic study, which demonstrated that through the implementation of certain measures—such as reducing the time required for market authorization, adjusting prices, and strengthening communication—it will be possible to promote medicine exports.
In this context, she highlighted that most medicines produced in Tunisia are generics, which account for 70% of transactions, in addition to biosimilars that are also exported.
According to Fenina, Tunisia possesses the necessary expertise and skills to promote investment and exports in the pharmaceutical sector.
It is worth noting that Tunisia produces 3,168 generic medicines and 46 biosimilars, according to Abderrazak Hedhili, Director General of the National Medicines Agency.
A market worth $1.69 billion
The size of Tunisia's pharmaceutical market was estimated at $1.69 billion in 2021, and total revenue is expected to grow by 12.9% between 2022 and 2029, reaching nearly $4.47 billion. This was reported by the website 'Maximisemarketsearch' in a recent overview of the Tunisian pharmaceutical market.
According to the same source, 'Tunisia is one of the few countries in Africa with a pharmaceutical sector equipped with sophisticated management and advanced technologies, both in terms of quality and product safety.
Local production of generic medicines accounts for approximately 49%, while imports make up about 51%. Tunis is home to around 39 pharmaceutical companies in the region.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
African Manager
24-03-2025
- African Manager
Pharmaceutical industry: New perspectives taking shape
Tunisia has taken strategic measures to strengthen its autonomy in the pharmaceutical sector. A recent working meeting held at the Ministry of Health resulted in a series of decisions aimed at accelerating the licensing procedures for medicines, ensuring their rapid availability on the market. These decisions include enhancing export opportunities, expanding regional partnerships to position Tunisia as a pharmaceutical hub, and digitizing the sector to ensure transparency and smooth distribution. Present at the meeting, Health Minister Mustapha Ferjani emphasized the directives of the President of the Republic, which aim to achieve pharmaceutical sovereignty, boost local production, and rely on national expertise to ensure health security. The meeting brought together representatives from the National Chamber of the Pharmaceutical Industry (CNIP) as well as directors of structures involved in the pharmaceutical sector. The adopted measures also include encouraging investments in pharmaceutical industries, supporting new laboratories, and revising price compensation mechanisms to protect the competitiveness of local manufacturers. These initiatives reflect the nation's commitment to achieving true health autonomy, aiming to meet citizens' needs and reduce dependence on foreign imports. Over 20% of Medicines Produced in Tunisia Are Exported More than 20% of medicines manufactured in Tunisia are exported to numerous countries, including Libya, sub-Saharan Africa, the Middle East, and Europe, according to Nadia Fenina, Director General of the Investment and Export Promotion Unit for Health Services at the Ministry of Health. In a recent statement to the media on the sidelines of the first International Days of Generic Medicines and Biosimilars held in Tunis, Fenina revealed that the value of these exports ranges between 250 and 300 million dinars. 'The goal is to reach 1.4 billion dinars within four years,' she noted. Fenina emphasized that this target was set based on the results of a strategic study, which demonstrated that through the implementation of certain measures—such as reducing the time required for market authorization, adjusting prices, and strengthening communication—it will be possible to promote medicine exports. In this context, she highlighted that most medicines produced in Tunisia are generics, which account for 70% of transactions, in addition to biosimilars that are also exported. According to Fenina, Tunisia possesses the necessary expertise and skills to promote investment and exports in the pharmaceutical sector. It is worth noting that Tunisia produces 3,168 generic medicines and 46 biosimilars, according to Abderrazak Hedhili, Director General of the National Medicines Agency. A market worth $1.69 billion The size of Tunisia's pharmaceutical market was estimated at $1.69 billion in 2021, and total revenue is expected to grow by 12.9% between 2022 and 2029, reaching nearly $4.47 billion. This was reported by the website 'Maximisemarketsearch' in a recent overview of the Tunisian pharmaceutical market. According to the same source, 'Tunisia is one of the few countries in Africa with a pharmaceutical sector equipped with sophisticated management and advanced technologies, both in terms of quality and product safety. Local production of generic medicines accounts for approximately 49%, while imports make up about 51%. Tunis is home to around 39 pharmaceutical companies in the region.'
African Manager
21-11-2024
- African Manager
Tunisia: Health ministry working on new law to regulate internet sales of medicines
Secretary General of the National Council of the Order of Pharmacists, Thouraya Naifer, denounced on Mosaique FM, the phenomenon of the sale of food supplements and herbal remedies on the Internet, warning of the dangers it poses to the health of citizens. She explained that the Ministry of Health is currently working on a law to regulate the manufacture and sale of these products in response to the alarming spread of this phenomenon. She pointed out that the sale of dietary supplements over the Internet had increased sharply since the announcement of the draft law, reaching fraudulent levels, particularly in the case of medicines purportedly made from plants and claiming to cure several diseases at once. She called for the law to be speeded up and for the online marketing of these products to be regulated. She also urged the public not to put their health at risk and to consult their pharmacist before buying any supplements.
African Manager
16-11-2024
- African Manager
Pharmaceutical industry: New prospects emerging
Tunisia's pharmaceutical sector continues to forge ahead despite ongoing challenges. Despite the difficulties facing the country, the industry remains robust, meeting the population's need for medicines and making a significant contribution to the country's economic prosperity. And it has done so in the most challenging of times, as demonstrated by its resilience in the face of the COVID-19 public health crisis. Aware of the stakes involved, the government has stepped up its commitment to the sector since the late 1980s. At that time, the state-owned industry was meeting only between 5% and 6% of the country's medication needs. Policy clarification in terms of investment in the sector and specific incentives have therefore stimulated a positive dynamic in the sector,' points out the National Council of the Tunisian Pharmacists Association (CNOPT). During his visit to Sfax on November 13, Minister of Health, Mustapha Ferjani, confirmed his ministry's intention to radically restructure the Tunisian pharmaceutical industry while guaranteeing its autonomy. He added that medicines produced in Tunisia cover about 75% of Tunisians' needs and stressed that it is possible to reach 100% of pharmaceutical production thanks to the skills of national managers, including doctors and pharmacists with Tunisian university degrees. Ferjani also explained that the Tunisian Pharmaceutical Industries Company, which resumed its activities two months ago after a two-year hiatus, is now able to guarantee the safety of medicines following its restructuring. As for the central pharmacy, the health minister said that it provides all essential medicines, particularly for cancer and other diseases, but that there can sometimes be a shortage. Pharmaceuticals in Tunisia: a USD 1.69 billion market The size of the Tunisian pharmaceutical market is estimated at 1.69 billion US dollars in 2021, and total sales are expected to grow by 12.9% between 2022 and 2029, reaching almost 4.47 billion USD. These are the findings of a recent review of the Tunisian pharmaceutical market published by the Maximisemarketsearch website. According to the same source, 'Tunisia is one of the few countries in Africa to have a pharmaceutical sector with sophisticated management and advanced technologies, both in terms of product quality and safety. Local production of generic medicines is about 49% and imports are about 51%. Tunis has around 39 pharmaceutical companies in the region. Regulatory and legal challenges For a long time, the management of medicines in Tunisia was fragmented between several structures, which hindered the development of the pharmaceutical sector. The National Agency for Medicines and Health Products, long called for by professionals in the sector, was created by Law No. 2023-2 of July 12, 2023. This agency, which is seen as a strong signal of the State's commitment to consolidating and developing this sector, brings together the structures for managing medicines and health products. Its mission is to establish a coherent national policy in the pharmaceutical sector by strengthening controls on the manufacture, registration, import, export, distribution and marketing of these products. However, despite the praise expressed by local pharmaceutical manufacturers for the creation of this agency, the sector still faces major challenges, not least of which is the legislation in force, which is considered 'inappropriate' for encouraging its expansion. The legislation in question is essentially Law 73 on the Pharmaceutical Professions, which now needs to be urgently revised (…).
